MicroRNA miR-92a-3p regulates breast cancer cell proliferation and metastasis via regulating B-cell translocation gene 2 (BTG2)

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cominetti MR, Altei WF, Selistre-de-araujo HS. Metastasis inhibition in breast cancer by targeting cancer cell extravasation. Breast Cancer (Dove Med Press). 2019 Apr;18(11):165–178.
   Google Scholar
• Duijf PHG, Nanayakkara D, Nones K, et al. Mechanisms of genomic instability in breast cancer. Trends Mol Med. 2019 Jul;25(7):595–611.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215–233.
   PubMed Web of Science ®Google Scholar
• Xie T, Huang M, Wang Y, et al. MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer. Cell Physiol Biochem. 2016;40(1–2):62–76.
   PubMed Web of Science ®Google Scholar
• Huang ZM, Ge HF, Yang CC, et al. MicroRNA-26a-5p inhibits breast cancer cell growth by suppressing RNF6 expression. Kaohsiung J Med Sci. 2019 Aug;35(8):467–473.
   PubMed Web of Science ®Google Scholar
• You F, Luan H, Sun D, et al. miRNA-106a promotes breast cancer cell proliferation, clonogenicity, migration, and invasion through inhibiting apoptosis and chemosensitivity. DNA Cell Biol. 2019 Feb;38(2):198–207.
   PubMed Web of Science ®Google Scholar
• Han M, Wang Y, Guo G, et al. microRNA-30d mediated breast cancer invasion, migration, and EMT by targeting KLF11 and activating STAT3 pathway. J Cell Biochem. 2018 Nov;119(10):8138–8145.
   PubMed Web of Science ®Google Scholar
• Li X, Guo S, Min L, et al. miR-92a-3p promotes the proliferation, migration and invasion of esophageal squamous cell cancer by regulating PTEN. Int J Mol Med. 2019 Sep;44(3):973–981.
   PubMed Web of Science ®Google Scholar
• Song H, Zhang Y, Liu N, et al. miR-92a-3p exerts various effects in glioma and glioma stem-like cells specifically targeting CDH1/β-Catenin and Notch-1/Akt signaling pathways. Int J Mol Sci. 2016 Oct 27;17(11):1799.
   Web of Science ®Google Scholar
• Lim IK. TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule. J Cancer Res Clin Oncol. 2006 Jul;132(7):417–426.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liang X, Zhang L, et al. MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget. 2016 Aug 9;7(32):51943–51954.
   PubMedGoogle Scholar
• Huang CS, Zhai JM, Zhu XX, et al. BTG2 is down-regulated and inhibits cancer stem cell-like features of side population cells in hepatocellular carcinoma. Dig Dis Sci. 2017 Dec;62(12):3501–3510.
   PubMed Web of Science ®Google Scholar
• Shen S, Zhang R, Guo Y, et al. A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer. Mol Oncol. 2018 Jun;12(6):913–924.
   PubMed Web of Science ®Google Scholar
• Powell E, Shao J, Yuan Y, et al. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res. 2016 Jan 27;18(1):13.
   PubMedGoogle Scholar
• Zhang YJ, Wei L, Liu M, et al. BTG2 inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-negative breast cancer cells. Tumour Biol. 2013 Jun;34(3):1605–1613.
   PubMedGoogle Scholar
• Yin C, Zhang G, Sun R, et al. miR-185-5p inhibits F-actin polymerization and reverses epithelial mesenchymal transition of human breast cancer cells by modulating RAGE. Mol Med Rep. 2018 Sep;18(3):2621–2630.
   PubMed Web of Science ®Google Scholar
• Wang H, Tan Z, Hu H, et al. microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer. 2019 Jul 27;19(1):738.
   PubMedGoogle Scholar
• Huo W, Qi F, Wang K. Long non-coding RNA FER1L4 inhibits prostate cancer progression via sponging miR-92a-3p and upregulation of FBXW7. Cancer Cell Int. 2020 Feb 28;20(1):64.
   PubMed Web of Science ®Google Scholar
• Ke TW, Wei PL, Yeh KT, et al. MiR-92a promotes cell metastasis of colorectal cancer through PTEN-mediated PI3K/AKT pathway. Ann Surg Oncol. 2015 Aug;22(8):2649–2655.
   PubMed Web of Science ®Google Scholar
• He G, Zhang L, Li Q, et al. miR-92a/DUSP10/JNK signalling axis promotes human pancreatic cancer cells proliferation. Biomed Pharmacother. 2014 Feb;68(1):25–30.
   PubMed Web of Science ®Google Scholar
• McFall T, McKnight B, Rosati R, et al. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem. 2018 Jan 26;293(4):1163–1177.
   PubMed Web of Science ®Google Scholar
• Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 2010 Jan;222(1):66–72.
   PubMed Web of Science ®Google Scholar
• Matsuda S, Rouault J, Magaud J, et al. In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett. 2001 May 25;497(2–3):67–72.
   PubMed Web of Science ®Google Scholar
• Duriez C, Moyret-Lalle C, Falette N, et al. BTG2, its family and its tutor. Bull Cancer. 2004 Jul-Aug;91(7–8):E242–53.
   PubMedGoogle Scholar
• Li YJ, Dong BK, Fan M, et al. BTG2 inhibits the proliferation and metastasis of osteosarcoma cells by suppressing the PI3K/AKT pathway. Int J Clin Exp Pathol. 2015 Oct 1;8(10):12410–12418.
   PubMed Web of Science ®Google Scholar
• Sundaramoorthy S, Devanand P, Ryu MS, et al. TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2-AKT1-NFAT1-PHLPP2 signaling axis. J Cancer Res Clin Oncol. 2018 Aug;144(8):1445–1462.
   PubMed Web of Science ®Google Scholar
• Venza M, Visalli M, Beninati C, et al. miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells. Int Immunopharmacol. 2016 Nov;40:235–243.
   PubMed Web of Science ®Google Scholar